報價延遲最少15分鐘:2025/07/03 03:52 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.29 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.71/--
|
|
企業價值
8.31M
|
| 資產負債 |
|
每股賬面淨值
0.05
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
9.36M
|
|
每股收益
0.00
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/03 03:52 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer. |